Grifols S.A. - Asset Resilience Ratio
Grifols S.A. (GRF) has an Asset Resilience Ratio of 0.04% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Grifols S.A. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Grifols S.A.'s Asset Resilience Ratio has changed over time. See GRF equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Grifols S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GRF market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.11 Million | 0.04% |
| Total Liquid Assets | €7.11 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Grifols S.A. maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grifols S.A. Industry Peers by Asset Resilience Ratio
Compare Grifols S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Chongqing Lummy Pharmaceutical
SHE:300006 |
Drug Manufacturers - General | -0.19% |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507 |
Drug Manufacturers - General | 26.41% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Grifols S.A. (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Grifols S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | €24.18 Million ≈ $28.27 Million |
€21.41 Billion ≈ $25.02 Billion |
-0.43pp |
| 2023-12-31 | 0.54% | €116.14 Million ≈ $135.78 Million |
€21.44 Billion ≈ $25.07 Billion |
+0.34pp |
| 2022-12-31 | 0.20% | €43.26 Million ≈ $50.58 Million |
€21.53 Billion ≈ $25.18 Billion |
-10.35pp |
| 2021-12-31 | 10.55% | €2.03 Billion ≈ $2.37 Billion |
€19.23 Billion ≈ $22.49 Billion |
+9.60pp |
| 2020-12-31 | 0.95% | €145.74 Million ≈ $170.38 Million |
€15.27 Billion ≈ $17.86 Billion |
-10.16pp |
| 2019-12-31 | 11.11% | €1.73 Billion ≈ $2.02 Billion |
€15.54 Billion ≈ $18.17 Billion |
+11.11pp |
| 2018-12-31 | 0.01% | €822.00K ≈ $961.00K |
€12.48 Billion ≈ $14.59 Billion |
+0.00pp |
| 2017-12-31 | 0.01% | €702.00K ≈ $820.71K |
€10.92 Billion ≈ $12.77 Billion |
0.00pp |
| 2016-12-31 | 0.01% | €957.00K ≈ $1.12 Million |
€10.13 Billion ≈ $11.84 Billion |
+0.00pp |
| 2015-12-31 | 0.01% | €509.00K ≈ $595.07K |
€9.60 Billion ≈ $11.23 Billion |
0.00pp |
| 2014-12-31 | 0.01% | €476.00K ≈ $556.49K |
€8.45 Billion ≈ $9.88 Billion |
+0.00pp |
| 2013-12-31 | 0.00% | €232.00K ≈ $271.23K |
€5.84 Billion ≈ $6.83 Billion |
-0.29pp |
| 2011-12-31 | 0.29% | €16.90 Million ≈ $19.76 Million |
€5.81 Billion ≈ $6.79 Billion |
-0.39pp |
| 2010-12-31 | 0.69% | €12.95 Million ≈ $15.14 Million |
€1.89 Billion ≈ $2.21 Billion |
+0.19pp |
| 2009-12-31 | 0.50% | €8.22 Million ≈ $9.61 Million |
€1.66 Billion ≈ $1.94 Billion |
-0.07pp |
| 2008-12-31 | 0.56% | €6.66 Million ≈ $7.78 Million |
€1.18 Billion ≈ $1.38 Billion |
-0.19pp |
| 2007-12-31 | 0.75% | €7.08 Million ≈ $8.28 Million |
€939.57 Million ≈ $1.10 Billion |
+0.07pp |
| 2006-12-31 | 0.68% | €6.23 Million ≈ $7.29 Million |
€913.67 Million ≈ $1.07 Billion |
+0.60pp |
| 2005-12-31 | 0.08% | €661.00K ≈ $772.78K |
€821.68 Million ≈ $960.63 Million |
-- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more